Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Acolbifene

Known as: (2S)-3-(4-Hydroxyphenyl)-4-methyl-2-(4-(2-(1-piperidinyl)ethoxy)phenyl)-2H-1-benzopyran-7-ol 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
The estrogen receptor alpha (ERalpha) has proven to be the single most important target in breast cancer over the last 30 years… 
Highly Cited
2006
Highly Cited
2006
Purpose: We tested whether a selective estrogen receptor modulator (SERM) and a rexinoid are active for prevention and treatment… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
2006
2006
Tamoxifen is currently used as adjuvant therapy for estrogen receptor (ER) positive breast cancer patients and as a… 
Highly Cited
2005
Highly Cited
2005
To assess the specific estrogenic and/or androgenic effects of a potential novel hormone replacement therapy, we have examined… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
2005
2005
OBJECTIVE:The selective estrogen receptor (ER) modulator (SERM) acolbifene (ACOL), a potent and pure antiestrogen in the mammary… 
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2005
2005
Although approved for the treatment of hormone-dependent breast cancer as well as for the prevention of breast cancer in high… 
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
2005
2005
This study aimed to identify the mechanisms of the hypolipidemic action of the selective estrogen receptor modulator (SERM… 
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
2005
2005
EM-652 (acolbifene) analogs have been synthesized as selective estrogen receptor modulators. Substitution on the nitrogen atom of… 
2004
2004
PURPOSE To determine the efficacy and safety of EM-800 (SCH-57050), the precursor of acolbifene, a new, highly potent, orally… 
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2002
Highly Cited
2002
Cardiovascular disease is the leading cause of morbidity and mortality in postmenopausal women. EM-652 (acolbifene) is a fourth…